Categories: NewsPharmaceutical

Anju to Highlight Newly Launched MA Knowledge at DIA MICC 2024 in London

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

CHICAGO, Sept. 19, 2024 /PRNewswire/ — Anju, a leading provider of adaptive life sciences software solutions, is pleased to announce its participation as an exhibitor at the upcoming DIA Medical Information & Communications Conference scheduled to take place in London on September 24-25th. DIA MICC brings together medical information professionals for discussions, learning, and practical sessions around improving customer experiences across the industry.

Anju is proud to present MA Knowledge, a state-of-the-art application that offers access to verified and carefully curated medical information content, tailored to meet the unique needs of each field representative. With efficient content filtering and search features, MA Knowledge consistently delivers medical information that matches user profiles and their areas of interest.

“Anju’s commitment to innovation was the driving force behind the development of MA Knowledge,” said Reed McLaughlin, General Manager of Anju’s Medical Affairs Division. “We recognized an opportunity to vastly improve the field representatives’ customer experience by providing quick access to trustworthy, curated information.”

Attendees at DIA MICC 2024 are encouraged to visit Anju at booth 8 to explore their adaptable solutions and discuss how Anju’s best-in-class technology can help to streamline your medical information and scientific communications process. Anju’s team of experts will be on hand to answer questions and discuss how Anju’s solutions can meet the unique needs of your organization.

About Anju:
Anju Software is a customer-first organization providing adaptable life science solutions for clinical research, medical affairs, and data science. TrialMaster, IRMS MAX, and TA Scan, the company’s flagship products, lead the way in reducing complexities in the drug and device discovery and commercialization process. Anju is a portfolio company of Abry Partners serving the worldwide pharmaceutical, biotech and contract research Life Sciences markets.

For media inquiries, please contact:
John F. Kouten
JFK Communications, Inc.
+1 609.241.7352
jfkouten@jfkhealth.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/anju-to-highlight-newly-launched-ma-knowledge-at-dia-micc-2024-in-london-302253584.html

SOURCE Anju Software

Staff

Recent Posts

FinThrive Introduces Agentic AI at HFMA 2025 to Help Customers Transform Healthcare Revenue Cycle Management Performance

Company to also highlight advancements in denials and underpayments management and speak to the measurable…

13 hours ago

FinThrive Debuts Denials and Underpayments Analyzer, a Unified Solution for Denials and Underpayments, at HFMA 2025

Next generation analyzer helps hospitals protect revenue before it's lost by delivering timely end-to-end visibility…

13 hours ago

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction…

16 hours ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project as Federal Support for Blockchain Grows

Dr. Anosh Ahmed repurposes West Side warehouse into blockchain innovation center, targeting 250+ jobs and…

16 hours ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project Amid National Pro-Crypto Policy Shift

Dr. Anosh Ahmed converts vacant West Side warehouse into blockchain innovation hub, creating 250+ jobs…

16 hours ago

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits…

16 hours ago